1,792 Shares in Stryker Co. (NYSE:SYK) Acquired by Bank of Jackson Hole Trust

Bank of Jackson Hole Trust acquired a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 1,792 shares of the medical technology company’s stock, valued at approximately $645,000.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Whittier Trust Co. raised its stake in Stryker by 24.0% during the 3rd quarter. Whittier Trust Co. now owns 4,150 shares of the medical technology company’s stock valued at $1,499,000 after buying an additional 804 shares during the last quarter. Foundations Investment Advisors LLC raised its stake in Stryker by 10.0% during the 3rd quarter. Foundations Investment Advisors LLC now owns 1,753 shares of the medical technology company’s stock valued at $633,000 after buying an additional 160 shares during the last quarter. Sky Investment Group LLC raised its stake in Stryker by 3.7% during the 3rd quarter. Sky Investment Group LLC now owns 15,119 shares of the medical technology company’s stock valued at $5,462,000 after buying an additional 533 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Stryker by 1.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 11,236 shares of the medical technology company’s stock valued at $4,059,000 after buying an additional 187 shares during the last quarter. Finally, Eastern Bank raised its stake in Stryker by 313.5% during the 3rd quarter. Eastern Bank now owns 3,730 shares of the medical technology company’s stock valued at $1,347,000 after buying an additional 2,828 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 0.1 %

SYK opened at $385.44 on Wednesday. The firm has a 50-day simple moving average of $377.44 and a two-hundred day simple moving average of $367.94. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a market capitalization of $147.08 billion, a PE ratio of 49.67, a price-to-earnings-growth ratio of 2.90 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. Analysts forecast that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SYK shares. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Piper Sandler reiterated an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Stifel Nicolaus upped their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. BTIG Research upped their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup upped their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $420.68.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.